United States 114th Congress Status: Died 1 R cosponsors

HR 2570 — Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015

Last action — Received in the Senate and Read twice and referred to the Committee on Finance.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. Died in session

This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 (Sec. 2) This bill amends title XVIII (Medicare) of the Social Security Act (SSAct) with respect to criteria for qualifying as a meaningful user of electronic health records (meaningful EHR user). For any payment year after 2015 any patient encounter of an eligible professional occurring at an eligible ambulatory surgical center shall not be treated as one in determining whether an eligible professional qualifies as a meaningful EHR user. (Sec. 3) HHS shall establish a three-year demonstration program to test the use of value-based insurance design methodologies under the eligible Medicare Advantage (MA) plans offered by MA organizations under Medicare part C. "Value-based insurance design methodology" is one for identifying specific prescription medications, and clinical services payable under Medicare, for which copayments, coinsurance, or both would improve the management of specific chronic clinical conditions because of the high value and effectiveness of such medications and services for such specific chronic clinical conditions, as approved by HHS. HHS may expand the duration and scope of the demonstration program to an appropriate extent if specified requirements are met. (Sec. 4) Payment amounts are prescribed for infusion drugs and biologicals furnished through durable medical equipment (DME) on or after January 1, 2017. (Sec. 5) It is the sense of Congress that HHS: has incorrectly interpreted the determination of blended benchmark amounts as prohibiting the provision of any Medicare quality incentive payments with respect to MA plans that exceed the payment benchmark cap for the area served by those plans; and should immediately apply quality incentive payments with respect to such MA plans without regard to limits. (Sec. 6) $220 million shall be available to the Medicare Improvement Fund during and after FY2020. (Sec. 7) DME competitive acquisition programs shall not cover infusion drugs and biologicals.

Bill Text

We don't have the full text on file for this bill yet.

Read HR 2570 on the official United States source →

Action History

  1. Received in the Senate and Read twice and referred to the Committee on Finance.

  2. The title of the measure was amended. Agreed to without objection.

  3. Motion to reconsider laid on the table Agreed to without objection.

  4. On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4479-4480)

  5. DEBATE - The House proceeded with forty minutes of debate on H.R. 2570.

  6. Considered under suspension of the rules. (consideration: CR H4479-4481)

  7. Mr. Brady (TX) moved to suspend the rules and pass the bill, as amended.

  8. Referred to the Subcommittee on Health.

  9. Referred to the Subcommittee on Health.

  10. Referred to House Energy and Commerce

  11. Referred to House Ways and Means

  12. Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  13. Introduced in House

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 546 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (546)

546 members have not signed on to this bill.

Show all 546 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HR 2570 do?
Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 (Sec. 2) This bill amends title XVIII (Medicare) of the Social Security Act (SSAct) with respect to criteria for qualifying as a meaningful user of electronic health records (meaningful EHR user). For any payment year after 2015 any patient encounter of an eligible professional occurring at an eligible ambulatory surgical center shall not be treated as one in determining whether an eligible professional qualifies as a meaningful EHR user. (Sec. 3) HHS shall establish a three-year demonstration program to test the use of value-based insurance design methodologies under the eligible Medicare Advantage (MA) plans offered by MA organizations under Medicare part C. "Value-based insurance design methodology" is one for identifying specific prescription medications, and clinical services payable under Medicare, for which copayments, coinsurance, or both would improve the management of specific chronic clinical conditions because of the high value and effectiveness of such medications and services for such specific chronic clinical conditions, as approved by HHS. HHS may expand the duration and scope of the demonstration program to an appropriate extent if specified requirements are met. (Sec. 4) Payment amounts are prescribed for infusion drugs and biologicals furnished through durable medical equipment (DME) on or after January 1, 2017. (Sec. 5) It is the sense of Congress that HHS: has incorrectly interpreted the determination of blended benchmark amounts as prohibiting the provision of any Medicare quality incentive payments with respect to MA plans that exceed the payment benchmark cap for the area served by those plans; and should immediately apply quality incentive payments with respect to such MA plans without regard to limits. (Sec. 6) $220 million shall be available to the Medicare Improvement Fund during and after FY2020. (Sec. 7) DME competitive acquisition programs shall not cover infusion drugs and biologicals.
Who sponsors HR 2570?
HR 2570 is sponsored by Diane Black (R).
What is the current status of HR 2570?
This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HR 2570?
Track HR 2570 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 2570

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 2570

Last checked for changes about 13 hours ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →